{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-176138","form_type":"8-K","ticker":"ASMB","cik":"0001426800","company_name":"ASSEMBLY BIOSCIENCES, INC.","filed_at":"2025-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.965228+00:00","generated_at":"2026-05-17T16:16:19.533515+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Assembly Bio reports 94% reduction in HSV-2 shedding with ABI-5366 350mg weekly in Phase 1b","bullets":["94% reduction in HSV-2 shedding rate (p<0.01) for 350mg weekly dose vs placebo over 29-day evaluation.","98% reduction in high viral load shedding (p<0.05) and 94% reduction in genital lesion rate (p<0.01) with 350mg weekly.","ABI-5366 well-tolerated; majority of TEAEs Grade 1-2; no serious adverse events reported.","PK supports weekly and potential monthly dosing; Phase 2 preparation initiated; chronic tox studies complete.","Gilead has opt-in rights to the helicase-primase program; ABI-1179 and monthly cohort data expected fall 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-176138","json":"https://secwatch.observer/filing/0001193125-25-176138.json","markdown":"https://secwatch.observer/filing/0001193125-25-176138.md","text":"https://secwatch.observer/filing/0001193125-25-176138.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1426800/000119312525176138/0001193125-25-176138-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1426800/000119312525176138/d802767d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T16:16:19.533515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}